Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Common Equity for 3 consecutive years, with $43.2 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 11.89% year-over-year to $43.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.2 million (down 11.89% YoY) and the FY2025 annual result came in at $43.9 million, down 9.21% from the prior year.
• Common Equity rose to $43.2 million in Q4 2025 per ZYBT's latest filing, from $41.7 million in the prior quarter.
• Over the last five years, Common Equity for ZYBT reached as high as $49.1 million in Q4 2024 and fell as low as $41.7 million in Q2 2025.
• A 3-year average of $45.3 million and a median of $45.2 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity gained 4.16% — and 2025, when it retreated 11.89%.
• Year by year, Common Equity stood at $47.1 million in 2023, then rose by 4.16% to $49.1 million in 2024, then fell by 11.89% to $43.2 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $43.2 million, $41.7 million, and $49.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.